XSPRAY PHARMA and Handa Therapeutics Enter Strategic Licensing Partnership for Advanced Therapeutic Development

“`html

Xspray Pharma Secures Licensing Deal With Handa Therapeutics

Published: November 27, 2023 at 8:00 AM PST

Updated: November 27, 2023 at 8:00 AM PST

Stockholm, Sweden – Xspray Pharma, a Pharmaceutical Company focused on improving drug formulations, has announced a significant licensing agreement with Handa Therapeutics. The Collaboration will focus on developing and commercializing an improved version of Dexloryx, a medication used to treat adults with schizophrenia.

The Agreement grants Xspray Pharma exclusive rights to develop, manufacture, and market an enhanced formulation of Dexloryx utilizing its proprietary NanoCrystal technology. This Technology aims to improve the drug’s bioavailability and potentially enhance its therapeutic effects. Handa Therapeutics will receive an upfront payment, milestone payments tied to development progress, and royalties on future sales.

“We are very pleased to partner with Handa Therapeutics on this vital project,” said Per Wågeus, CEO of Xspray Pharma. “Dexloryx is a valuable medication, and we believe our NanoCrystal technology can considerably improve its performance and benefit patients.”

The deal represents a key step for Xspray Pharma in expanding its portfolio of enhanced drug formulations. The Company’s NanoCrystal technology has the potential to address challenges associated with poorly soluble drugs, a common issue in the pharmaceutical industry. This Partnership underscores the growing demand for innovative drug delivery systems.

Handa Therapeutics expressed enthusiasm for the collaboration, highlighting Xspray pharma’s expertise in drug formulation and NanoCrystal technology. The Companies will work closely together to advance the development program and bring the improved Dexloryx formulation to market.

Understanding NanoCrystal Technology and its Impact on Pharmaceuticals

NanoCrystal technology represents a significant advancement in drug delivery. It involves reducing the size of drug particles to the nanoscale, increasing their surface area and improving their solubility. This can lead to enhanced bioavailability, faster absorption, and potentially reduced dosage requirements.

The benefits of NanoCrystal technology extend beyond improved drug performance. It can also enable the reformulation of existing drugs, extending their patent life and creating new market opportunities. Several Pharmaceutical companies are actively exploring NanoCrystal technology to address challenges associated with drug solubility and bioavailability.

The Pharmaceutical Industry is increasingly focused on developing innovative drug delivery systems to improve patient outcomes and address unmet medical needs. Technologies like NanoCrystal are playing a crucial role in this effort, offering the potential to transform the way drugs are formulated and administered.

Frequently Asked Questions About Xspray Pharma and Drug Formulation

1. what is Xspray Pharma’s core technology? Xspray Pharma specializes in NanoCrystal technology, a method for improving the bioavailability of drugs by reducing particle size.
2. What is dexloryx used for? Dexloryx is a medication used in the treatment of schizophrenia in adults.
3. How does NanoCrystal technology improve drug bioavailability? By reducing particle size, NanoCrystal technology increases the surface area of the drug, leading to faster dissolution and absorption.
4. What are milestone payments in a licensing agreement? Milestone payments are payments made to the licensor upon achieving specific development or regulatory milestones.
5. What is the potential benefit of this partnership for patients? The improved formulation of Dexloryx could offer enhanced therapeutic effects and potentially reduce side effects.
6. Is NanoCrystal technology widely used in the pharmaceutical industry? Yes, NanoCrystal technology is gaining increasing traction as a solution for improving the performance of poorly soluble drugs.
7. What does this agreement mean for Xspray Pharma’s future? This licensing deal expands Xspray Pharma’s portfolio and validates its NanoCrystal technology, positioning the company for further growth.

Disclaimer: this article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

What are your thoughts on this new partnership? Share your comments below and let us know!

{
"@context": "https://schema.org",
"@type": "NewsArticle",
"headline": "Xspray Pharma Secures Licensing Deal With Handa Therapeutics",
"image": [],
"datePublished": "2023-11-27T08:00:00-

How does the XSPRAY™ technology improve drug bioavailability compared to traditional methods?

XSPRAY PHARMA and Handa Therapeutics: A New Era in Therapeutic Innovation

The Strategic Licensing Partnership - A Deep Dive

XSPRAY PHARMA, a leader in innovative drug delivery systems, and Handa Therapeutics, specializing in novel therapeutic targets, have announced a strategic licensing partnership poised to accelerate the growth of advanced therapies. This collaboration focuses on leveraging XSPRAY's proprietary XSPRAY™ technology with Handa Therapeutics' promising pipeline of drug candidates.The agreement grants Handa Therapeutics exclusive licensing rights to utilize the XSPRAY™ platform for specific therapeutic areas, initially focusing on oncology and autoimmune diseases.

This isn't simply a technology transfer; it's a synergistic alignment of expertise. XSPRAY's technology addresses critical challenges in drug bioavailability and targeted delivery, while Handa therapeutics brings a robust portfolio of compounds with demonstrated pre-clinical efficacy. This partnership represents a significant step forward in precision medicine and personalized healthcare.

Understanding the XSPRAY™ Technology: Revolutionizing Drug Delivery

The core of this partnership lies in XSPRAY's unique drug delivery system. Unlike traditional methods, XSPRAY™ utilizes a micro-jet technology to deliver drugs directly into subcutaneous tissue. This bypasses the first-pass metabolism in the liver, leading to:

Enhanced Bioavailability: A greater percentage of the drug reaches systemic circulation.

Reduced Dosage: Lower doses can achieve the same therapeutic effect, minimizing side effects.

Improved Patient Compliance: Subcutaneous administration offers a more convenient and less invasive alternative to intravenous infusions or frequent oral medications.

Targeted Drug Delivery: The technology allows for precise drug placement, maximizing efficacy at the site of action.

This technology is especially relevant for biologics, peptides, and other molecules that struggle with poor oral absorption or rapid degradation. The benefits extend to cost-effectiveness in drug manufacturing and administration. Key terms related to this technology include subcutaneous drug delivery, micro-jet injection, bioavailability enhancement, and targeted therapies.

Handa Therapeutics' Pipeline: Fueling the Collaboration

Handa Therapeutics' contribution to this partnership is a portfolio of novel compounds targeting key pathways involved in cancer and autoimmune disorders. Their research focuses on:

Immuno-oncology: Developing therapies that harness the power of the immune system to fight cancer.

Targeted Therapies: Identifying and blocking specific molecular targets driving disease progression.

Inflammation Modulation: creating drugs that regulate the inflammatory response in autoimmune conditions.

Specifically, the initial focus will be on applying XSPRAY™ technology to Handa's lead candidate, HT-101, a novel inhibitor of [redacted - specific target data not publicly available], currently in pre-clinical development for the treatment of [redacted - specific cancer type]. Related search terms include immuno-oncology drugs, targeted cancer therapies, autoimmune disease treatments, and novel drug candidates.

Financial Implications and Partnership Structure

The licensing agreement includes an upfront payment from Handa Therapeutics to XSPRAY PHARMA, along with milestone payments tied to clinical development and regulatory approval. XSPRAY PHARMA is also eligible to receive royalties on future sales of products developed under the partnership. The financial details, while not fully disclosed, indicate a significant investment in the potential of this collaboration. This structure incentivizes both companies to drive the development process forward efficiently. Terms like licensing agreements, pharmaceutical partnerships, royalty payments, and biotech investment are relevant here.

Potential impact on the Pharmaceutical Landscape

This partnership has the potential to disrupt the pharmaceutical industry in several ways:

1. Accelerated Drug Development: Combining proven technologies and promising drug candidates can substantially shorten the time it takes to bring new therapies to market.
2. Improved Patient Outcomes: Enhanced drug delivery and targeted therapies can lead to more effective treatments with fewer side effects.
3. Expansion of Therapeutic Options: The collaboration opens up new possibilities for treating diseases that currently lack effective therapies.
4. Increased Investment in Drug Delivery Technologies: The success of this partnership could spur further investment in innovative drug delivery systems.

Real-World Applications & Future Outlook

While still in the early stages, the potential applications of this partnership are broad. Imagine a patient with rheumatoid arthritis receiving a monthly subcutaneous injection of a targeted therapy,eliminating the need for daily oral medications and their associated side effects. Or a cancer patient receiving a localized dose of chemotherapy directly into a tumor, minimizing damage to healthy tissues.

Looking ahead, XSPRAY PHARMA and Handa Therapeutics plan to expand the scope of their collaboration to include additional therapeutic areas and drug candidates. The success of HT-101 will be a critical indicator of the partnership's long-term viability. The future of personalized medicine, drug delivery innovation, and therapeutic development* looks brighter with collaborations like this one.